Incyte Bolsters Hematology Growth With $2 Billion Vega Buyout

Incyte will acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, in a transaction valued at up to $2 billion. The deal includes $1.25 billion upfront and up to $750 million in milestone-based payments tied to future sales. Closing is expected in the third quarter of 2026, subject to regulatory review and customary conditions.

The acquisition strengthens Incyte’s hematology pipeline by adding VGA039, a Phase 3 monoclonal antibody that could become the first subcutaneous prophylactic therapy for von Willebrand disease (VWD). The company views the transaction as an opportunity to expand into bleeding disorders while building on its established hematology franchise.

Novel Mechanism of Action

VGA039 targets Protein S, a natural anticoagulant that regulates clot formation. By modulating Protein S activity, the therapy enhances platelet adhesion and fibrin deposition, restoring normal hemostasis. Unlike factor replacement therapies that supplement missing clotting proteins, VGA039 works by enhancing the body’s natural clotting process. This approach could extend beyond VWD to other bleeding disorders.

VWD is the most common inherited bleeding disorder, affecting about 135,000 diagnosed individuals in the United States. Patients often experience recurrent bleeding episodes that impair quality of life. Current prophylactic options rely on intravenous factor replacement requiring two to three infusions weekly. VGA039’s once‑monthly subcutaneous administration could substantially reduce treatment burden and improve convenience.

 Phase 3 VIVID‑6 Trial

The pivotal Phase 3 VIVID‑6 study (NCT07115004) is evaluating VGA039 in patients with all VWD subtypes, including those with high bleeding burden. The global single‑arm crossover trial is assessing whether monthly subcutaneous dosing can reduce bleeding events compared with frequent intravenous prophylaxis.

Although efficacy data have not yet been reported, VGA039 has secured multiple FDA expedited designations, including Breakthrough Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease status. These highlight both the unmet need in VWD and the therapy’s potential for accelerated review.

Strategic Importance for Both Companies

Incyte Chief Executive Officer Bill Meury described VGA039 as a compelling late‑stage asset with encouraging early data, a clear development pathway, and potential to become a growth driver within the hematology portfolio.

Star Therapeutics Founder and CEO Adam Rosenthal emphasized that the transaction validates the company’s drug discovery strategy and ensures VGA039 will be advanced by a partner with global development and commercial expertise.

Financial and Commercial Outlook

Upon closing, Incyte will assume responsibility for completing Phase 3 development and pursuing regulatory submissions. The company expects to record an approximately $1.25 billion R&D charge in its third‑quarter and full‑year 2026 financial results.

If approved, VGA039 could become the first subcutaneous prophylactic therapy for VWD, shifting treatment away from frequent intravenous infusions toward once‑monthly self‑administration. Beyond VWD, Protein S modulation may support future development across other bleeding disorders.

With multiple FDA designations, ongoing Phase 3 evaluation, and potential to simplify long‑term disease management, VGA039 could emerge as a significant addition to Incyte’s hematology portfolio and an important new option for patients living with bleeding disorders.

Reference

Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders | Incyte